Terms: = Testicular cancer AND MUC16, CA125, CA-125 AND Treatment
7 results:
1. Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs.
Eoh KJ; Park J; Kim HM; Lee M; Kim YT
Yonsei Med J; 2021 Apr; 62(4):366-369. PubMed ID: 33779091
[TBL] [Abstract] [Full Text] [Related]
2. Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors.
Castro BGR; Souza CP; Andrade CEMDC; Vieira MA; Andrade DAP; Reis RD
Rev Bras Ginecol Obstet; 2019 Jul; 41(7):440-448. PubMed ID: 31344718
[TBL] [Abstract] [Full Text] [Related]
3. Clear cell carcinoma of testis: A review.
Lin M; Awalt H; Ayala AG; Ro JY
Ann Diagn Pathol; 2019 Jun; 40():26-29. PubMed ID: 30921621
[TBL] [Abstract] [Full Text] [Related]
4. [A case of testicular tumor of ovarian epithelial type].
Nishimoto M; Shimizu N; Kikuchi T; Kobayashi Y; Yamamoto Y; Minami T; Hayashi T; Tsuji H; Nozawa M; Yoshimura K; Ishii T; Uemura H
Hinyokika Kiyo; 2013 Nov; 59(11):753-7. PubMed ID: 24322416
[TBL] [Abstract] [Full Text] [Related]
5. Proteomics in prostate cancer biomarker discovery.
Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
[TBL] [Abstract] [Full Text] [Related]
6. PET imaging in the management of tumors of testis and ovary: current thinking and future directions.
Basu S; Rubello D
Minerva Endocrinol; 2008 Sep; 33(3):229-56. PubMed ID: 18846028
[TBL] [Abstract] [Full Text] [Related]
7. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract] [Full Text] [Related]
